Current clinical development of PI3K pathway inhibitors in glioblastoma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current clinical development of PI3K pathway inhibitors in glioblastoma
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 14, Issue 7, Pages 819-829
Publisher
Oxford University Press (OUP)
Online
2012-05-23
DOI
10.1093/neuonc/nos117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors
- (2017) K. P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of single-agent perifosine for recurrent pediatric solid tumors.
- (2017) O. J. Becher et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.
- (2017) I. Brana et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.
- (2017) C. Moldovan et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma.
- (2017) S. Dolly et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
- (2017) A. M. Traynor et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.
- (2017) A. Jimeno et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma.
- (2017) P. L. Nghiemphu et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
- (2017) F. A. Greco et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.
- (2017) H. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.
- (2017) G. Edelman et al. JOURNAL OF CLINICAL ONCOLOGY
- First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.
- (2017) U. Banerji et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.
- (2017) A. J. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
- (2017) B. Grana et al. JOURNAL OF CLINICAL ONCOLOGY
- A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.
- (2017) J. D. Peyton et al. JOURNAL OF CLINICAL ONCOLOGY
- Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors.
- (2017) F. Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
- (2011) Euphemia Leung et al. CANCER BIOLOGY & THERAPY
- Correlation of Somatic Mutation and Expression Identifies Genes Important in Human Glioblastoma Progression and Survival
- (2011) D. L. Masica et al. CANCER RESEARCH
- Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
- (2011) Arkaitz Carracedo et al. CELL CYCLE
- Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
- (2011) D. Koul et al. CLINICAL CANCER RESEARCH
- Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy
- (2011) H. M. Kantarjian et al. CLINICAL CANCER RESEARCH
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
- (2011) G. Prasad et al. NEURO-ONCOLOGY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Why do women have similar erythropoietin levels to men but lower hemoglobin levels?
- (2010) W. G. Murphy et al. BLOOD
- PTEN Signaling pathways in glioblastoma
- (2010) Dimpy Koul CANCER BIOLOGY & THERAPY
- An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo
- (2010) Craig Cherrin et al. CANCER BIOLOGY & THERAPY
- A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST
- (2010) Jean-Yves Blay CANCER TREATMENT REVIEWS
- Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia
- (2010) I. M. Ghobrial et al. CLINICAL CANCER RESEARCH
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
- (2010) Dora Dias-Santagata et al. EMBO Molecular Medicine
- First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours
- (2010) Clemens Unger et al. EUROPEAN JOURNAL OF CANCER
- North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
- (2010) Jann N. Sarkaria et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
- (2010) Aram F. Hezel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
- (2010) Wei-Gang Tong et al. JOURNAL OF CLINICAL ONCOLOGY
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
- (2010) P M Bhende et al. LEUKEMIA
- An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients
- (2010) François Ducray et al. Molecular Cancer
- Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma
- (2010) D. Koul et al. NEURO-ONCOLOGY
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma
- (2010) Q.-W. Fan et al. Science Signaling
- Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
- (2009) P Cao et al. BRITISH JOURNAL OF CANCER
- Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations
- (2009) G. Konstantinidou et al. CANCER RESEARCH
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
- (2009) C. C. Dibble et al. MOLECULAR AND CELLULAR BIOLOGY
- Peroxisome proliferator-activated receptor agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity
- (2009) N. T. Ihle et al. MOLECULAR CANCER THERAPEUTICS
- NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
- (2009) T.-J. Liu et al. MOLECULAR CANCER THERAPEUTICS
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
- (2009) Laura E. MacConaill et al. PLoS One
- PI3K Signaling in Glioma-Animal Models and Therapeutic Challenges
- (2008) Christine K. Cheng et al. BRAIN PATHOLOGY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
- (2008) N. T. Ihle et al. CANCER RESEARCH
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Malignant Gliomas in Adults
- (2008) Patrick Y. Wen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
- (2008) Qing-Bai She et al. PLoS One
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started